225 related articles for article (PubMed ID: 11981501)
21. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
22. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy.
Vander Els NJ; Miller V
Chest; 1998 Dec; 114(6):1779-81. PubMed ID: 9872221
[TBL] [Abstract][Full Text] [Related]
24. [A phase II multicenter study of gemcitabine in non small cell lung cancers].
Le Chevalier T; Gottfried M; Gatzemeier U; Shepherd F; Weynants P; Cottier B; Groen HJ; Rosso R; Mattson K; Cortes-Funes H; Tonato M; Burkes RL; Voi M; Ponzio A
Bull Cancer; 1997 Mar; 84(3):282-8. PubMed ID: 9207875
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study.
Bianco V; Rozzi A; Tonini G; Santini D; Magnolfi E; Vincenzi B; D'Angelillo R; Marchei P
Anticancer Res; 2002; 22(5):3053-6. PubMed ID: 12530041
[TBL] [Abstract][Full Text] [Related]
26. [Severe ischemic myopathy localized in an irradiated area following gemcitabine therapy].
Pariente A; Berthelémy P; Arotçarena R; Bénichou M; Calès V; Dujols JP
Presse Med; 2000 Oct; 29(30):1650. PubMed ID: 11089501
[No Abstract] [Full Text] [Related]
27. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer.
van Putten JW; Baas P; Codrington H; Kwa HB; Muller M; Aaronson N; Groen HJ
Lung Cancer; 2001; 33(2-3):289-98. PubMed ID: 11551424
[TBL] [Abstract][Full Text] [Related]
28. [Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)].
Fukuoka M; Negoro S; Kudo S; Furuse K; Nishikawa H; Takada Y; Kamei T; Niitani H; Taguchi T
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1825-32. PubMed ID: 8937493
[TBL] [Abstract][Full Text] [Related]
29. Veno-occlusive disease of the liver induced by gemcitabine.
Dobbie M; Hofer S; Oberholzer M; Herrmann R
Ann Oncol; 1998 Jun; 9(6):681. PubMed ID: 9681086
[No Abstract] [Full Text] [Related]
30. Gemcitabine hydrochloride: combination of activity and tolerability. Proceedings of a symposium. Jerusalem, Israel, November 14, 1993.
Anticancer Drugs; 1995 Dec; 6 Suppl 6():5-65. PubMed ID: 8718418
[No Abstract] [Full Text] [Related]
31. [New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
Depierre A; Westeel V; Jacoulet P
Bull Cancer; 2002 Aug; 89 Spec No():S76-9. PubMed ID: 12449034
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine--a major advance?
Thomas A; Steward WP
Ann Oncol; 1998 Dec; 9(12):1265-7. PubMed ID: 9932153
[No Abstract] [Full Text] [Related]
33. Severe pulmonary toxicity in a patient treated with gemcitabine.
Rosado MF; Kett DH; Schein RM; Baraona FJ; Sridhar KS
Am J Clin Oncol; 2002 Feb; 25(1):31-3. PubMed ID: 11823691
[TBL] [Abstract][Full Text] [Related]
34. Hemolytic-uremic syndrome caused by gemcitabine.
Nackaerts K; Daenen M; Vansteenkiste J; Vandevelde A; Van Bleyenbergh P; Demedts M
Ann Oncol; 1998 Dec; 9(12):1355. PubMed ID: 9932169
[No Abstract] [Full Text] [Related]
35. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
Maestu I; Gómez-Aldaraví L; Torregrosa MD; Camps C; Llorca C; Bosch C; Gómez J; Giner V; Oltra A; Albert A
Lung Cancer; 2003 Dec; 42(3):345-54. PubMed ID: 14644523
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review.
Hansen HH; Sørensen JB
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-38-S7-41. PubMed ID: 9194478
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
Anderson H; Hopwood P; Stephens RJ; Thatcher N; Cottier B; Nicholson M; Milroy R; Maughan TS; Falk SJ; Bond MG; Burt PA; Connolly CK; McIllmurray MB; Carmichael J
Br J Cancer; 2000 Aug; 83(4):447-53. PubMed ID: 10945489
[TBL] [Abstract][Full Text] [Related]
38. Vasculitis due to gemcitabine.
Voorburg AM; van Beek FT; Slee PH; Seldenrijk CA; Schramel FM
Lung Cancer; 2002 May; 36(2):203-5. PubMed ID: 11955656
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer.
Choi B; Robins HI; Schiller J; Mehta M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):175-9. PubMed ID: 18305938
[TBL] [Abstract][Full Text] [Related]
40. Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study.
Steward WP; Dunlop DJ; Cameron C; Talbot DC; Kleisbauer JP; Thomas P; Guerin JC; Perol M; Sanson C; Dabouis G
Anticancer Drugs; 1995 Dec; 6 Suppl 6():33-7. PubMed ID: 8718423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
